Myocardial infarction, left ventricle remodelation and cellular therapy

1. Widimsky P. Reperfusion damage or no-reflow damage in primary coronary interventions in acute myocardial infarction? Eur Heart J 2002; 23: 1076–1078.

2. Schomig A, Ndrepepa G, Mehilli J et al. Therapy-Dependent Influence of Time-to-Treatment Interval on Myocardial Salvage in Patients With Acute Myocardial Infarction Treated With Coronary Artery Stenting or Thrombolysis. Circulation 2003; 108: 1084–1088.

3. Stone GW, Brodie BR, Griffin JJ et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in‑hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. J Am Coll Cardiol 1998; 31: 23–30.

4. Aschermann M, Horak J, Reznicek V et al. Fibrinolytic therapy in acute myocardial infarct. Čas Lék Čes 2003; 142: 582–585.

5. Widimsky P, Gregor P, Dvorak J et al. The optimal diagnostic approach in myocardial infarct. Vnitř Lék 1993; 39: 160–165.

6. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20.

7. Lichtman JH, Spertus JA, Reid KJ et al. Acute Noncardiac Conditions and In-Hospital Mortality in Patients With Acute Myocardial Infarction. Circulation 2007; 116: 1925–1930.

8. Poloczek M, Kala P, Neugebauer P et al. ST‑segment resolution as a simple tool for the assessment of successful primary coronary intervention at a microvascular level. Vnitř Lék 2004; 50: 740–745.

9. Widimsky P, Zelizko M, Jansky P et al. The incidence, treatment strategies and outcomes of acute coronary syndromes in the „reperfusion network“ of different hospital types in the Czech Republic: results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry. Int J Cardiol 2007; 119: 212–219.

10. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146–1149.

11. Pfeffer MA, Pfeffer JM, Fishbein MC et al. Myocardial infarct size and ventricular function in rats. Circ Res 1979; 44: 503–512.

12. Bolognese L, Neskovic AN, Parodi G et al. Left Ventricular Remodeling After Primary Coronary Angioplasty: Patterns of Left Ventricular Dilation and Long‑Term Prognostic Implications. Circulation 2002; 106: 2351–2357.

13. Krupicka J, Gregor P, Budesinsky T et al. Echocardiographic quantification of changes in left ventricular kinetics in patients during hospitalization for a first myocardial infarct and treated with direct angioplasty. Vnitř Lék 2002; 48: 368–372.

14. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161–1172.

15. Opie LH, Commerford PJ, Gersh BJ et al. Controversies in ventricular remodelling. Lancet 2006; 367: 356–367.

16. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701–705.

17. Jain M, DerSimonian H, Brenner DA et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 103: 1920–1927.

18. Gulati R, Simari RD. Cell therapy for acute myocardial infarction. Med Clin North Am 2007; 91: 769–785.

19. Wollert KC. Cell therapy for acute myocardial infarction. Curr Opin Pharmacol 2008; 8: 202–210.

20. Yoon YS, Wecker A, Heyd L et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005; 115: 326–338.

21. Badorff C, Brandes RP, Popp R et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 2003; 107: 1024–1032.

22. Abdel-Latif A, Bolli R, Tleyjeh IM et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta‑analysis. Arch Intern Med 2007; 167: 989–997.

23. Martin‑Rendon E, Brunskill SJ, Hyde CJ et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J 2008; 29: 1807–1818.

24. Ott HC, Matthiesen TS, Brechtken J et al. The adult human heart as a source for stem cells: repair strategies with embryonic‑like progenitor cells. Nat Clin Pract 2007; 4 (Suppl 1): S27–S39.

25. Taylor DA, Atkins BZ, Hungspreugs P et al. Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929–933.

26. Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 92–95.

27. Fukuda K, Fujita J. Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice. Kidney Int 2005; 68: 1940–1943.

28. Mangi AA, Noiseux N, Kong D et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195–1201.

29. Menasche P. Myoblast‑based cell transplantation. Heart Fail Rev 2003; 8: 221–227.

30. Pagani FD, DerSimonian H, Zawadzka A et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003; 41: 879–888.

31. Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow‑up. Am Heart J 2004; 148: 531–537.

32. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634–637.

33. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430–436.

34. Jackson KA, Majka SM, Wang H et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107: 1395–1402.

35. Tse HF, Lau CP. Therapeutic angiogenesis with bone marrow-derived stem cells. J Cardiovasc Pharmacol Ther 2007; 12: 89–97.

36. Kajstura J, Leri A, Bolli R et al. Endothelial progenitor cells: neovascularization or more? J Mol Cell Cardiol 2006; 40: 1–8.

37. Itescu S, Kocher AA, Schuster MD. Myocardial neovascularization by adult bone marrow-derived angioblasts: strategies for improvement of cardiomyocyte function. Heart Fail Rev 2003; 8: 253–258.

38. Bartunek J, Vanderheyden M, Wijns W et al. Bone-marrow-derived cells for cardiac stem cell therapy: safe or still under scrutiny? Nature clinical practice 2007; 4 (Suppl 1): S100–S105.

39. Bartunek J, Wijns W, Heyndrickx GR et al. Timing of intracoronary bone-marrow-derived stem cell transplantation after ST‑elevation myocardial infarction. Nat Clin Pract 2006; 3 (Suppl 1): S52–S56.

40. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210–1221.

41. Lunde K, Solheim S, Aakhus S et al. Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J 2005; 39: 150–158.

42. Meluzin J, Janousek S, Mayer J et al. Three-, 6-, and 12-month results of autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction. Int J Cardiol 2007; 128: 185–192.

43. Kamihata H, Matsubara H, Nishiue T et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001; 104: 1046–1052.

44. Assmus B, Schachinger V, Zeiher AM. Regenerative therapy in cardiology: how distant is it from reality? Internist (Berl) 2006; 47: 1177–1182.

45. Fukuda K, Yuasa S. Stem cells as a source of regenerative cardiomyocytes. Circ Res 2006; 98: 1002–1013.

46. Li CJ, Gao RL, Yang YJ et al. Autologous bone marrow mononuclear cells and peripheral endothelial progenitor cells differentiation in myocardial ischemia reperfusion injury region in swine. Zhonghua Xin Xue Guan Bing Za Zhi (Chinese Journal of Cardiovascular Diseases) 2007; 35: 350–353.

47. Orlic D, Hill JM, Arai AE. Stem cells for myocardial regeneration. Circ Res 2002; 91: 1092–1102.

48. Li Y, Fukuda N, Yokoyama S et al. Effects of G‑CSF on cardiac remodeling and arterial hyperplasia in rats. Eur J Pharmacol 2006; 549: 98–106.

49. Pannitteri G, Petrucci E, Testa U. Coordinate release of angiogenic growth factors after acute myocardial infarction: evidence of a two‑wave production. J Cardiovasc Med (Hagerstown) 2006; 7: 872–879.

50. Kang HJ, Lee HY, Na SH et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 2006; 114: 1145–1151.

51. Fazel S, Cimini M, Chen L et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006; 116: 1865–1877.

52. Antonio Abbate GGLB-ZAB. Pathophysiologic role of myocardial apoptosis in post‑infarction left ventricular remodeling. J Cell Physiol 2002; 193: 145–153.

53. Kajstura J, Cheng W, Reiss K et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74: 86–107.

54. Baldi A, Abbate A, Bussani R et al. Apoptosis and post‑infarction left ventricular remodeling. J Mol Cell Cardiol 2002; 34: 165–174.

55. Orlic D. Stem cell repair in ischemic heart disease: an experimental model. Int J Hematol 2002; 76 (Suppl 1): 144–145.

56. Arnesen H, Lunde K, Aakhus S et al. Cell therapy in myocardial infarction. Lancet 2007; 369: 2142–2143.

57. Assmus B, Walter DH, Lehmann R et al. Intracoronary infusion of progenitor cells is not associated with aggravated restenosis development or atherosclerotic disease progression in patients with acute myocardial infarction. Eur Heart J 2006; 27: 2989–2995.

58. Meluzin J, Mayer J, Groch L et al. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am Heart J 2006; 152: 975.

59. Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST‑segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113–121.

60. Penicka M, Horak J, Kobylka P et al. Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized study. J Am Coll Cardiol 2007; 49: 2373–2374.

61. Penicka M, Widimsky P, Kobylka P et al. Images in cardiovascular medicine. Early tissue distribution of bone marrow mononuclear cells after transcoronary transplantation in a patient with acute myocardial infarction. Circulation 2005; 112: e63–e65.

62. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months‘ follow‑up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST‑elevation infarct regeneration) trial. Circulation 2006; 113: 1287–1294.

63. Menasche P, Hagege AA, Vilquin JT et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41: 1078–1083.

64. Herreros J, Prosper F, Perez A et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non‑acute myocardial infarction. Eur Heart J 2003; 24: 2012–2020.

65. Siminiak T, Kalawski R, Fiszer D et al. Autologous transplantation of skeletal myoblasts in the treatment of postinfarction left heart dysfunction: three-month follow‑up. Kardiol Pol 2004; 60 (Suppl 1): I–71–I–76.

66. Villa A, Sanchez PL, Fernandez-Aviles F. Ventricular arrhythmias following intracoronary bone marrow stem cell transplantation. Europace 2007; 9: 1222–1223.

67. Perin EC, Dohmann HF, Borojevic R et al. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110: II213–II218.

68. Tse HF, Thambar S, Kwong YL et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 2007; 28: 2998–3005.

69. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141–148.

70. Schachinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690–1699.

71. Huang RC, Yao K, Zou YZ et al. Long term follow‑up on emergent intracoronary autologous bone marrow mononuclear cell transplantation for acute inferior-wall myocardial infarction. Zhonghua Yi Xue Za Zhi 2006; 86: 1107–1110.

72. Suarez de Lezo J, Herrera C, Pan M et al. Regenerative therapy in patients with a revascularized acute anterior myocardial infarction and depressed ventricular function. Rev Esp Cardiol 2007; 60: 357–365.

73. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1–E7.

74. Kuethe F, Krack A, Fritzenwanger M et al. Treatment with granulocyte-colony stimulating factor in patients with acute myocardial infarction. Evidence for a stimulation of neovascularization and improvement of myocardial perfusion. Pharmazie 2006; 61: 957–961.

75. Kurdi M, Booz GW. G‑CSF‑based stem cell therapy for the heart–unresolved issues part A: paracrine actions, mobilization, and delivery. Congest Heart Fail 2007; 13: 221–227.

76. Yoshioka T, Ageyama N, Shibata H et al. Repair of infarcted myocardium mediated by transplanted bone marrow-derived CD34+ stem cells in a nonhuman primate model. Stem Cells 2005; 23: 355–364.

77. Yin CQ, Chen JL, Wang YF et al. Autologus bone marrow-derived mesenchymal stem cells intracoronary delivery after acute myocardial infarction in miniature pig. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27: 696–699.

78. Tse HF, Yiu KH, Lau CP. Bone marrow stem cell therapy for myocardial angiogenesis. Curr Vasc Pharmacol 2007; 5: 103–112.

79. Aviles FF, San Roman JA, Garcia Frade J et al. Intracoronary stem cell transplantation in acute myocardial infarction. Rev Esp Cardiol 2004; 57: 201–208.

80. Stamm C, Westphal B, Kleine HD et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361: 45–46.

81. Schachinger V, Erbs S, Elsasser A et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006; 27: 2775–2783.

82. Lunde K, Solheim S, Aakhus S et al. Exercise capacity and quality of life after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: results from the Autologous Stem cell Transplantation in Acute Myocardial Infarction (ASTAMI) randomized controlled trial. Am Heart J 2007; 154: 710–718.